Clinical trial NCT00612014: Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gastroparesis
Diabetes Mellitus
Keywords: delayed gastric emptying
symptomatic gastroparesis
diabetes mellitus
Lead sponsor: Tranzyme, Inc.
Sponsor class: INDUSTRY
First posted: 2008-02-11
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.

Detailed description: Subjects are randomized according to an adaptive randomization procedure.

Eligibility criteria: Inclusion Criteria:

* Subject has type 1 or type 2 diabetes mellitus
* Subject has documented diagnosis of gastroparesis (all of the following apply):

  * Confirmed delayed gastric emptying (see Appendix IV; properly conducted gastric emptying assessments within last 6 months acceptable)
  * AND a minimum 3 month history of relevant symptoms for gastroparesis (chronic postprandial fullness, bloating, epigastric discomfort, early satiety, belching after meal, postprandial nausea, vomiting).
  * AND a mean Gastroparesis Cardinal Symptom Index (GCSI) Score (2 week recall version) of ≥ 2.66
  * AND it is confirmed by endoscope that there are no obstructive lesions in the esophagus or stomach (endoscopy within prior 3 months acceptable)
* Subject has never had a gastrectomy, nor major abdominal surgery or any evidence of bowel obstruction within the previous 12 months
* Dosage of any concomitant medications has been stable for at least 3 weeks
* HbA1c level is ≤ 10.0%
* Subject has a BMI \< 30
* Subject body weight is ≤ 100 kg
* If female, post-menopausal for the past 12 months, surgically sterile (i.e. tubal ligation, hysterectomy), or using an adequate method of birth control (i.e., oral contraceptives, double barrier method, IUD cover) or sterilized partner

Exclusion Criteria:

* Subject has acute severe gastroenteritis
* Subject has a gastric pacemaker
* Subject is on chronic parenteral feeding
* Subject has daily persistent severe vomiting
* Subject has pronounced dehydration
* Subject has had diabetic ketoacidosis in last 4 weeks
* Subject has a history of eating disorders (anorexia nervosa, binge eating, bulimia)
* Subject has a marked baseline prolongation of QT/QTc interval (repeated demonstration of a QTc interval \>450 ms for male / \>470 ms for female)
* Subject has a history of additional risk factors for Torsades de Pointes (heart failure, chronic hypokalemia, family history of Long QT Syndrome)
* Subject requires use of concomitant medication that prolongs the QT interval

  * List provided to clinical sites
* Subject has history of cardiovascular ischemia in previous 12 months or acute myocardial infarction (MI) or unstable angina
* Subject requires use of concomitant medication that is known to interact with isoenzyme CYP3A4 and the combination with an CYP3A4 inhibitor is known to introduce a clinically significant drug interaction

  * List provided to clinical sites
* Subject has a history of psychiatric disorder or cognitive impairment that would interfere with participation in the study
* Subject has a history of alcoholism
* Subject is taking regular daily narcotics
* Subject has a known history of Hep B, Hep C or HIV
* Subject has severely impaired renal function (creatinine clearance \< 30 mL/min)
* Subject has severe impairment of liver function, defined as albumin level ≤ 2.5 gm/dL and/or prothrombin time \>6 seconds over control (INR \> 2.3)
* Subject has participated in an investigational study within 30 days prior to or received TZP-101 within 90 days prior to study initiation
* Subject is pregnant or is breast-feeding

Primary outcomes:
measure: Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.
timeFrame: after 4 dosing days
Secondary outcomes:
measure: Cumulative GSA score after each dosing event and after all dosing events
timeFrame: every 30 minutes for 4 hours
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: California Pacific Medical Center
state: California
city: Anderson
country: United States
facility: Central Indiana Gastroenterology Group
state: Indiana
city: Kansas City
country: United States
facility: Kansas University Medical Center
state: Kansas
city: Louisville
country: United States
facility: University of Louisville
state: Kentucky
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
city: Cochin
country: India
facility: Amrita Institute of Medical Sciences Research Center (AIMS)
state: Kerala
city: Bergen
country: Norway
facility: Haukeland University Hospital
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
city: Sheffield
country: United Kingdom
facility: Royal Hallamshire Hospital
Study officials:
References: